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INTRODUCTION
The internal mammary lymph nodes (IMLN) comprise the 
second most important regional nodal basin in breast cancer 
followed by the axillary lymph nodes (ALN). Metastasis to 
IMLN is well known as a poor prognostic indicator and has 
been reported in less than 30% of dissected patients. However, 
many clinicians have reported that surgical dissection of IMLN 
does not improve the outcome of breast cancer patients [1-3]. 
Currently, it is widely accepted that prophylactic dissection in 
clinically negative IMLN is not recommended as a standard 
surgical treatment. Moreover, because of the morbidity and 
uncertain benefit of surgical IMLN excision, majority of IMLN 
metastasis patients are treated with adjuvant therapy, such as 
chemotherapy or radiation therapy, as an alternative method.
Johnson et al. [4] suggested that the pathological status of 
the internal mammary sentinel lymph node (IMSLN) is the 
same as that of the axillary SLN; thus, if the pathological state 
of IMSLN could be predicted, IMLN may not need to be   
excised. Veronesi et al. [5] have suggested that selective IMSLN 
excision facilitated by radioactive labeled tracing method is a 
simple and safe technique and may provide maximum prog-
nostic value, similar to the current use of axillary SLN biopsy. 
Therefore, many researchers have attempted the use of IMSLN 
biopsy with lymphoscintigraphy. Some reports have suggested 
the importance of IMSLN biopsy for accurate staging, decreas-
ing the likelihood of the required treatment being overlooked, 
and as an important prognostic indicator [6-8], while others 
disagree on the additional surgical excision of the IMLN [9,10]. 
However, most studies have been limited to descriptive obser-
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Purpose: Internal mammary lymph node (IMLN) metastasis is an 
important prognostic indicator in breast cancer. However, the 
necessity of internal mammary sentinel lymph node biopsy for 
accurate staging, for choosing adjuvant treatment, and as a 
prognostic indicator, has remained controversial. Methods: From 
January 2001 to December 2006, 525 female breast cancer pa-
tients underwent radical surgery after preoperative lymphatic 
scintigraphy. We retrospectively analyzed the follow-up results, 
recurrences, and deaths of all patients. Results: There was no 
significant difference in the clinicopathological characteristics 
between the axilla and the IMLN groups. The median follow-up 
period was 118.8 months (range, 7-122 months) in the axilla 
group and 107.7 months (range, 14-108 months) in the IMLN 
group. During the median follow-up period, the breast cancer-
related death rate in the axilla group was 3.6%, which was not 
significantly different from that of the IMLN group (1.3%) (p=
0.484). The five-year survival rates did not differ between the two 
groups (p=0.306). The overall recurrence rate and the loco-         
regional recurrence rate also did not differ between the two 
groups (p=0.835 and p=0.582, respectively). The recurrence 
rate of IMLN (both ipsilateral and contralateral) metastasis was 
very low, accounting for 0.5% in the axilla group and 1.3% in the 
IMLN group (p=0.416). Conclusion: The long-term follow-up       
results showed that there was no significant difference in both 
overall outcome and regional recurrence between the two groups. 
Therefore, the requirement for identification of nodal basins out-
side the axilla or IMLN sentinel biopsy should be reconsidered.
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vations of early experiences and inconsistent results, and there 
is still insufficient evidence in terms of the efficacy and clinical 
significance of IMSLN biopsy. 
The efficiency of IMSLN surgical staging elicits additional 
consideration, particularly in patients with early breast cancer. 
The purpose of this study is to investigate the clinical features 
of tumors with IMLN drainage and to determine the clinical 
significance and long-term outcomes for IMSLN in early breast 
cancer.
METHODS
Patients and procedures
From January 2001 to December 2006, 525 female patients 
with early stage breast cancer underwent lymphatic scintigra-
phy followed by radical surgery at Sungkyunkwan University 
School of Medicine. Following lymphatic scintigraphy, the 
ALNs were identified during surgery by tracing radioactivity, 
but not all hot spots in the internal mammary chain were   
explored. Patients with clinically positive nodes were excluded 
as were patients with clinically advanced (stage III or IV)  
tumors. Using medical records, we retrospectively analyzed 
patient interviews, clinical characteristics, follow-up results, 
recurrences, and deaths.
Lymphatic scintigraphy was performed by injecting 1 mL of 
Technetium 99
m tin-colloid into the subareolar area. After 
60-90 minutes, the frontal and lateral views were acquired. 
The patients then underwent surgery on the same day. A blue 
dye was injected into the periareolar area intraoperatively and 
a combination of two methods was used for axillary SLN biop-
sy. Axilla group was defined as patients with a hot spot on the 
axilla but without an uptake in the IMLN area. All patients 
with IMLN hot spot detected with or without uptake in the 
axillary region were included in the IMLN group. The staging 
system was based on the 7th edition of the American Joint 
Committee on Cancer (AJCC).
Breast conserving surgery was performed if possible and 
margin was evaluated by frozen biopsy at operation and   
confirmed by final pathology. The primary end point was 
overall survival from the time of the operation until death due 
to breast cancer-related causes. Locoregional (LR) recurrence 
was defined as recurrences in the ipsilateral breast, chest wall, 
axillary, supraclavicular, or internal mammary lymph nodes, 
or in the skin of the chest wall or axilla. Breast cancer develop-
ment in the contralateral breast was not included in the LR 
area. Disease-free survival was defined as the period between 
the day of the breast cancer surgery until LR or distant recur-
rences of breast cancer. 
Statistical analysis
A comparative analysis of the two groups was performed. 
Baseline clinical and histological variables between each group 
was assessed with SPSS for Windows version 18.0 (SPSS Inc., 
Chicago, USA) using the Pearson chi-square test. A mean age 
comparison was done with the Kruskal-Wallis test. Multivari-
ate analyses were conducted using logistic regression and the 
Cox regression method. Cumulative overall survival (OS) rate 
and disease-free survival (DFS) rate were estimated by the   
Kaplan-Meier method. The log rank test was used for compar-
ison of survival outcome between the subgroups according to 
ALN metastasis and radiotherapy. Any local recurrence of 
distant metastasis was included in the analysis. The cut-off 
value for statistical significance was set at 0.05. The χ
2 test was 
used to determine the differences in the clinicopathological 
features between the two groups. 
RESULTS
Among the 525 early stage breast cancer patients, no uptake 
in either the axilla or IMLN was observed in 55 cases (10.4%) 
and 11 cases (2.1%) were found to have uptake in only IMLN. 
Axillary SLN was detected in all cases. Among the 470 patients 
exhibiting uptake (excluding the 55 patients in whom there 
was no uptake), 393 were included in the axillary uptake only 
group (74.9%) and 77 patients (14.7%) were included in the 
IMLN uptake group. 
Comparison of clinicopathological characteristics
There were no significant differences in the median age and 
body mass index between the two groups (p=0.189 and 
p=0.433, respectively). Tumor location was subdivided into 
inner and outer, upper and lower. Multifocal lesions, central 
locations, and subareolar locations were categorized as “other.” 
In both groups, tumors were most frequently located in the 
outer half and upper half. The type of operation did not differ 
between groups. Breast-conserving surgery was more frequent 
in both groups (p=0.594). The results of postoperative final 
pathological staging revealed that stage 1 was most frequent in 
both groups, with 198 cases (50.4%) in the axillary uptake 
only group and 40 cases (51.9%) in the IMLN uptake group. 
Also, there was no significant difference in the distribution of 
tumor, node, metastasis (TNM) stages between the two groups. 
ALN metastasis was the most frequent pattern in the axillary 
uptake only group (23.4%), but this observation was not statis-
tically significant. Molecular profiles including hormone recep-
tor (HR) and HER2 overexpression were also not significantly 
different between the two groups. Post-operative adjuvant 
therapies, including radiation, chemo, and hormonal, was 100   Min Young Koo, et al.
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similar in both groups (Table 1).
DFS and OS analysis
Among the 470 patients, 15 (3.2%) died of breast cancer 
during a median follow-up period of 119.2 months (range, 
7-124 months), and breast cancer-related relapse occurred in 
46 (9.8%) patients during a median follow-up period of 109.8 
months (range, 7-122 months). LR recurrence was found in 
25 patients (5.3%). Recurrence in the IM lymphatic chain was 
found in 3 cases (0.6%). One of these patients underwent  
partial mastectomy, while the other two underwent total  
mastectomy. Of these three patients, the one who underwent 
total mastectomy and SLN biopsy was stage I (T1N0), the one 
who underwent lumpectomy was stage II (T2N1), and the 
third patient who underwent total mastectomy was stage II 
(T1N1). The former 2 patients were included in the axillary 
uptake group and the latter patient was included in the IMLN 
uptake group.
The median follow-up period was 118.8 months (range, 
7-122 months) in the axillary uptake group and 107.7 months 
(range, 14-108 months) in the IMLN group. During these fol-
low-up periods, the breast cancer-related death rate in the ax-
illary uptake only group was 3.6%, which was not statistically 
different from that in the IMLN group (1.3%) (p=0.484). 
The 5-year rate also did not differ between the two groups (p=
0.306). The overall recurrence rate and the LR-specific recur-
rence rate did not differ between the two groups (p=0.835 
and p=0.582, respectively). The 5-year DFS rate and LR-spe-
cific DFS rate were not different between the two groups (p=
0.962 and p=0.723, respectively) (Table 2). In particular, the 
recurrence rate of IMLN (both ipsilateral and contralateral) 
was very low, with a rate of 0.5% in the axillary uptake only 
group and 1.3% in the IMLN uptake group (p=0.416).
Survival analysis using the Kaplan-Meier survival curve 
also produced similar results (p=0.306). Survival analysis 
using the Kaplan-Meier survival curve also did not show any 
difference between the two groups for DFS or LR recurrence 
specific DFS (p=0 .962 and p=0.723, respectively) (Figure 1).
Table 2. Breast cancer specific death rate and recurrence rate 
Follow-up 
(months)*
Events  
No. (%)
5YRS rate
(%)
p-value
†
Death 0.306
   Axilla only 118.8 (7-122) 14 (3.6) 97.6
   IMLN 107.1 (14-108)   1 (1.3) 98.6
   Total 121.2 (7-124) 15 (3.2) 97.8
Recurrence 0.962
   Axilla only 111.9 (7-122) 38 (9.7) 92
   IMLN 95.1 (8-1.3)     8 (10.4) 93.3
   Total 110.8 (7-122) 46 (9.8) 92.4
LR recurrence
   Axilla only 111.6 (7-122) 20 (5.1) 96 0.723
   IMLN 98.4 (8-103)   5 (6.5) 95.8
   Total 115.5 (7-122) 25 (5.3) 96.1
5YSR=5 year survival; IMLN=internal mammary lymph node; LR=locoregional.
*Median (range); 
†Log-rank test.
Table 1. Clinicopathologic features of the breast cancer patients 
Axilla only  
No. (%)
IMLN  
No. (%)
p-value
Age (yr)* 46 (23-79) 47 (27-68) 0.189
†
BMI (kg/m
2)* 23.2 (16.2-46.1) 23.1 (17-41.3) 0.433
†
Location
   Inner    103 (26.2)    17 (22.1) 0.207
‡
   Outer 224 (57)    52 (67.5)
   Others
§      66 (16.8)      8 (10.4)
   Upper    276 (70.2) 57 (74) 0.454
‡
   Lower      69 (17.6)      9 (11.7)
   Others
§      48 (12.2)    11 (14.3)
Operation 0.594
‡
   PM    272 (69.2)    51 (66.2)
   TM    121 (30.8)    26 (33.8)
Histology 0.791
‡
   DCIS      62 (15.8)    11 (14.3)
   IDC    281 (71.5)    56 (72.7)
   Others
ll      50 (12.7) 10 (13)
TNM stage 0.906
‡
   0   62 (16)    11 (14.3)
   1    198 (50.4)    40 (51.9)
   2    122 (30.8)    23 (29.9)
   3    11 (2.8)    3 (3.9)
ALN metastasis 0.097
†
   Yes      92 (23.4)    11 (14.3)
   No    301 (76.6)    66 (85.7)
HR expression 0.541
‡
   Yes    284 (74.3)    56 (74.7)
   No      98 (25.7)    19 (25.3)
Her2  0.735
‡
   Yes      63 (16.7)    11 (14.7)
   No    314 (83.3)    64 (85.3)
Radiation therapy 0.686
‡
   Yes 275 (70)    52 (67.5)
   No 118 (30)    25 (32.5)
Chemotherapy 0.608
‡
   Yes    240 (61.1)    50 (64.9)
   No    153 (38.9)    27 (35.1)
Hormone therapy 0.787
‡
   Yes    273 (69.5)    55 (71.4)
   No    120 (30.5)    22 (28.6)
Total    393 (74.9)    77 (14.7) 470 (89. 6)
IMLN=internal mammary lymph node; BMI=body mass index; PM=partial 
mastectomy; TM=total mastectomy; DCIS=ductal carcinoma in situ; IDC= 
invasive ductal carcinoma; TNM=tumor, node, metastasis; ALN=axillary lymph 
node; HR=hormone receptor.
*Median (range); 
†Kruskal-Wallis test; 
‡Fisher’s exact test; 
§Others include mul-
tifocal lesions, central location, subareolar location, borderline location; 
llOthers 
include lobular, mucinous, tubular, papillary micropapillary cribriform, medullary, 
mixed, metaplastic subtypes.Outcome of Internal Mammary Lymph Node 101
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A detailed analysis showed that ALN metastasis was not  
associated with the outcome of IMLN uptake patients, in either 
overall DFS outcome or LR-specific DFS outcome (Figure 2A 
and 2B). Moreover, radiation did not affect overall or LR-DFS   
outcome in IMLN uptake patients (Figure 2B).
DISCUSSION
With the recent use of preoperative lymphoscintigraphy 
and improved techniques, IMSLN biopsy has become clini-
cally feasible and applicable with greatly decreased morbidity 
compared to IMLN dissection. Different techniques for IMSLN 
biopsy are used at different institutes and are associated with 
different detection rates [11]. The amount of radioisotope  
injection, time interval between the injection, and the lympho-
scintigraphy, or the type of operation may have an effect on 
the IMLN detection rate. In general, IMSLN drainage is found 
in up to approximately 25% of patients during preoperative 
lymphoscintigraphy [4,8,9]. The IMLN is usually visualized 
simultaneously with ALN, and the incidence of isolated   
lymphatic drainage to IMLN has been estimated to be 1-8% 
[6,8,10,12,13]. Comparable to previous reports, approximately 
10% of our patients showed IMLN uptake on lymphoscintig-
raphy, and isolated IMLN drainage was found in 2.1% of   
patients. Few studies have presented a strong association   
between tumor location and lymphatic drainage to the inter-
nal mammary chain and tumor aggressiveness [1,4]. In this 
study, tumor location was not associated with stronger inter-
nal mammary drainage, but IMLN uptake tended to have a 
slightly decreased association with axillary metastasis.
The IMLN metastasis rate with successful IMSLN biopsy 
has been reported to be approximately 14%, a success rate that 
is lower than the actual detection rate [4,8,9]. Overall, the   
incidence of IMLN metastasis among breast cancer patients 
has been estimated to be less than 3% [9,14]. Moreover, due to 
advances in SLN biopsy techniques along with the surgeon’s 
experience, the success rate may increase over time; however, 
complications are currently encountered in approximately 
4.6-8% of patients, which is slightly higher than the metastasis 
rate in IMSLN [8,9,14]. IMSLN excision is associated with 
technical issues such as a higher morbidity rate, a lower   
metastasis rate in IMSLN than complication incidence, and 
limited surgeon experience and technical skills. In this study, 
only one patient underwent an intraoperative IMSLN biopsy, 
which was negative on frozen section analysis and permanent 
section analysis, with no biopsy-related morbidity. 
It is not feasible to directly compare IMSLN biopsy with   
resection of all IMLN in the same patients because the uptake 
of IMLN in lymphoscintigraphy does not represent metastasis 
in the IMLN [9]. In the literature, less than 1% of node-positive 
breast cancer patients who underwent mastectomy and   
chemotherapy, but not radiation therapy, developed IM recur-
rence [15]. In this study, all 3 IMLN recurrent patients (0.6%) 
underwent chemo-radiation therapy. van Rijk et al. [16]  
explained that the failure of extra-axillary SLN biopsy is the 
cause of extra-axillary nodal recurrence of breast cancer. 
These authors also found that all IMLN metastasis developed 
24, 46, and 63 months after surgery. Even though we assumed 
that IMLN uptake in patients indicated metastasis or micro-
metastases at the time of the diagnosis, the recurrence rate did 
not differ between the two groups. IMLN recurrence was 
equally rare in both the axillary uptake group and the IMLN 
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Figure 1. Survival analysis of the axillary uptake group and the internal mammary lymph node (IMLN) uptake group using a Kaplan-Meier survival curve. 
(A) Breast cancer-specific overall survival outcome (p=0.306). (B) Breast cancer-specific disease-free survival outcome (p=0.962). (C) Locoregional 
disease-free survival outcome (p=0.723). 102   Min Young Koo, et al.
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uptake group, with a relatively long time interval between  
diagnosis and recurrence.
IMLN metastasis is an important prognostic factor in breast 
cancer patients [1,17-19]. However, several studies have dem-
onstrated that surgical dissection of IMLN is not associated 
with increasing rate of survival. Several trials have failed to 
prove the advantage of surgical dissection of IMLN, and oth-
ers have demonstrated that the reduction of IMLN recurrence 
by calculation does not improve survival outcome in early 
breast cancer patients [5,20]. This study also suggests that pre-
dominant drainage to the IMLN area is not associated with 
IMLN involvement and long-term outcome, even in the theo-
retical overestimation of IMLN containing micro or   
macro-metastasis at the time of diagnosis. In particular, early 
stage breast cancer patients are not appropriate candidates for 
IMSLN biopsy. 
Although, IMLN metastasis without ALN metastasis is 
rarely found in early stage breast cancer [21], ALN positivity 
is known to be a risk factor for IMLN metastasis [22]. In this 
study, the presence of ALN metastasis did not affect the  
outcome for DFS in either group. ALN metastasis was less 
likely to occur in patients with IMLN drainage, although this 
trend was not statistically significant. Veronesi et al. [5] report-
ed that the annual death rate of axillary node negative/IMLN-
Figure 2. Subgroup analysis of survival outcome between the axillary uptake group and the internal mammary lymph node (IMLN) uptake group using 
the Kaplan-Meier survival curve. (A) Disease-free survival outcome according to axillary lymph nodes metastasis (p=0.932 and p=0.631, respective-
ly). (B) Locoregional disease-free survival of IMLN patients according to radiation therapy (p=0.893, and p=0.705, respectively).
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positive patients was not significantly different from that of 
axillary node positive/IMLN-negative patients. Others have 
also presented comparable significance for IMLN metastasis 
compared to axillary metastases, showing that the prognosis 
of patients with disease limited to axillary or IMLN is inter-
mediate between that of patients with negative nodes and 
those with IM and ALN metastases [18]. Further, radiation 
therapy did not affect the DFS outcome in the present study. 
Previously published randomized controlled trials reported 
that post-mastectomy radiation therapy resulted in a signifi-
cant improvement in survival [23,24]. Veronesi et al. [25] have 
also reported that IMLN radiation may have an effective role 
in the local control according to results on a large series. On 
the other hand, some reports have shown that irradiation in 
the IMLN shows no long-term survival benefits [2,26,27]. Trials 
are still ongoing to address this issue. Adjuvant treatment may 
play an important role when there is IMLN metastasis.
Biopsy results confirming the pathological state of IMLN 
for patients included in this study was absent. Therefore, a   
direct comparison analysis between IMSLN metastasis and 
pathologically confirmed IMSLN tumor-free patients was not 
possible. Discrepancy and possible bias are the main limitations 
of the current study. However, this is the largest observational 
analysis and the first review of IMLN detected by lympho- 
scintigraphy in terms of long-term outcome and prognostic 
significance. Subset analysis of the breast tumor, the treatment 
of which may benefit from IMSLN biopsy in early or advanced 
stage breast cancer, is open for future discussion.
The long-term follow-up results for early stage breast cancer 
patients showed that there was no significant difference in the 
survival outcome of patients with or without prominent 
IMLN drainage. Recurrence in a LR area including the inter-
nal mammary lymphatic chain was very low and did not   
differ between the two groups. ALN metastasis or additional 
radiation therapy did not affect the DFS outcome of breast 
cancer patients with internal mammary lymphatic drainage. 
Surgical exploration may also increase the risk of the interfer-
ing adjuvant treatment schedule without any advantage. 
Therefore, solid based clinical research may be required to 
clarify the necessity of IMSLN biopsy. Moreover, in a clinical 
setting, the authors suggest that IMSLN biopsy can be omitted 
in selected cases of early stage breast cancer without ALN   
metastasis. 
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